首页> 外国专利> Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86

Uses of soluble CTLA4 (cytotoxic T-lymphocyte-associated protein 4) fusion molecules mutated from wild-type CTLA4 to retain the ability to bind CD80 and/or CD86

机译:从野生型CTLA4突变而来的可溶性CTLA4(细胞毒性T淋巴细胞相关蛋白4)融合分子用于保持结合CD80和/或CD86的能力

摘要

Described are soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4 per gram. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 regions are mutated. The mutant molecules described may also include a second amino acid sequence that increases the solubility of the mutant molecule.
机译:所描述的是可溶性CTLA4突变分子,其与CD80和/或CD86抗原的亲合力大于每克野生型CTLA4或未突变的CTLA4。可溶性CTLA4分子具有包含CTLA4的细胞外结构域的第一氨基酸序列,其中S25-R33区域和M97-G107区域内的某些氨基酸残基被突变。所述的突变分子还可以包括第二氨基酸序列,其增加了突变分子的溶解度。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号